Are lorlatinib and lorlatinib the same drug?

Lorlatinib and lorlatinib are the same anti-cancer drug, but they are transliterated differently in different contexts. Their common English name is Lorlatinib. This is the case because drugs often have International Nonproprietary Names (INN) in the international market, and different countries and regions translate and transliterate them according to their language and phonetic rules to better communicate with local medical professionals and patients. It is sold under the trade name Lorbrena overseas, and after being launched domestically, it is sold under the name Lorlatinib. Lorlatinib is commonly used to treat adult patients with metastatic non-small cell lung cancer (NSCLC) who are anaplastic lymphoma kinase (ALK)-positive in a U.S. Food and Drug Administration (FDA) trial.

Lorlatinib is a third-generation ALK inhibitor. It precisely inhibits the activity of ALK receptors and effectively blocks the growth and spread of tumor cells, thereby achieving the treatment of non-small cell lung cancer. The design of this drug also takes into account the penetrability of the blood-brain barrier, allowing it to also play a therapeutic role in tumor metastasis in the brain. In clinical application, lorlatinib has demonstrated significant therapeutic effects. It can not only prolong the survival period of patients, but also improve their quality of life. For those patients whose disease has progressed despite treatment with other ALK inhibitors, lorlatinib undoubtedly provides them with new treatment options and hope.

However, although lorlatinib has significant therapeutic effects, it also has certain side effects and limitations in use. Therefore, when using this drug, you need to strictly follow the doctor's instructions and conduct relevant examinations and monitoring regularly.